Why a kidney disease drug approval in China is just the start for this S.F. company
December 18, 2018 at 17:18 PM EST
After 25 years, FibroGen won its first drug approval, a treatment for anemia in chronic kidney disease patients in China. It hopes to follow that up with approvals in the United States, Japan and Europe over the next year.
